Volume 52, Issue 3 , Pages 475-485, September 2008
Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression
Background
In patients with primary glomerulonephritis (GN), antiproteinuric response to angiotensin-converting enzyme (ACE) inhibitors plus angiotensin receptor blockers (ARBs) versus either monotherapy is undefined because of the small size of studies and high heterogeneity of response.
Study Design
Meta-analysis/metaregression.
Setting & Population
Randomized clinical trials (RCTs).
Selection Criteria for Studies
RCTs published from January 1996 to April 2007. Studies were excluded if information about levels of proteinuria was not available, patients had kidney disease other than primary GN, or if they had end-stage renal disease.
Intervention
ACE inhibitor plus ARB versus monotherapy with 1 of these drug classes.
Outcomes
Absolute changes in proteinuria (primary), blood pressure, serum potassium level, and glomerular filtration rate (GFR; secondary).
Results
We found 13 RCTs including 425 patients with primary GN with proteinuria ranging from 0.8 to 7.9 g/d of protein and age from 25 to 60 years. Combination treatment decreased proteinuria by 0.60 g/d (95% confidence interval, 0.40 to 0.80) versus ACE-inhibitor monotherapy and 0.54 g/d (95% confidence interval, 0.30 to 0.78) versus ARB monotherapy. Baseline levels of proteinuria explained most between-study variability of the antiproteinuric response to combination therapy versus monotherapies. Systolic and diastolic blood pressure, GFR, age, and diagnosis of immunoglobulin A nephropathy did not modify antiproteinuric response. ACE-inhibitor plus ARB therapy did not change GFR, whereas it increased serum potassium levels (by 0.10 mEq/L versus ACE-inhibitor and 0.19 mEq/L versus ARB therapy) and decreased blood pressure.
Limitations
Only published data are included.
Conclusions
The antiproteinuric response to ACE-inhibitor plus ARB therapy versus either monotherapy is consistently greater and strictly related to baseline proteinuria, associated with only moderate increase in serum potassium levels, and not peculiar to immunoglobulin A nephropathy.
Index Words: Chronic kidney disease, proteinuria, angiotensin II, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers
To access this article, please choose from the options below
Originally published online as doi:10.1053/j.ajkd.2008.03.008 on May 8, 2008.
PII: S0272-6386(08)00582-9
doi:10.1053/j.ajkd.2008.03.008
© 2008 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved.
Volume 52, Issue 3 , Pages 475-485, September 2008
